Pemvidutide vs Tirzepatide
Comparison of Altimmune's dual GLP-1/glucagon agonist pemvidutide with tirzepatide's GLP-1/GIP approach for obesity and metabolic disease.
Last updated: January 28, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Pemvidutide
Dossier overview
Tirzepatide
Dossier overview
Overview
Pemvidutide (ALT-801) is Altimmune’s investigational dual GLP-1/glucagon receptor agonist, while tirzepatide is Eli Lilly’s approved GLP-1/GIP dual agonist. These compounds represent different dual agonist strategies for obesity.
Key distinction: Different secondary receptors - pemvidutide activates glucagon receptors while tirzepatide activates GIP receptors, leading to potentially different metabolic profiles.
Key Facts
| Aspect | Pemvidutide | Tirzepatide |
|---|---|---|
| Developer | Altimmune | Eli Lilly |
| Class | GLP-1/Glucagon dual agonist | GLP-1/GIP dual agonist |
| FDA Status | Investigational (Phase 2) | Approved |
| Target Indications | Obesity, NASH | T2D, Obesity |
Mechanism Comparison
| Aspect | Pemvidutide | Tirzepatide |
|---|---|---|
| GLP-1 Receptor | Agonist | Agonist |
| Second Target | Glucagon receptor (agonist) | GIP receptor (agonist) |
| Weight loss mechanism | Appetite + energy expenditure | Appetite + insulin/metabolism |
| Liver effects | Potential direct NASH benefit | Indirect via weight loss |
How They Work
Pemvidutide:
- GLP-1 agonism reduces appetite and food intake
- Glucagon agonism increases energy expenditure
- Glucagon may promote hepatic lipid oxidation
- Dual mechanism may preserve lean mass during weight loss
- Potential direct effects on fatty liver disease
Tirzepatide:
- GLP-1 agonism for appetite suppression
- GIP agonism enhances insulin secretion
- Combined effect on glucose metabolism
- Potent weight loss through appetite reduction
- Liver benefits primarily through weight loss
Glucagon vs GIP: Different Approaches
| Effect | Glucagon Agonism (Pemvidutide) | GIP Agonism (Tirzepatide) |
|---|---|---|
| Blood glucose | Can increase (counterregulated by GLP-1) | Generally neutral/beneficial |
| Energy expenditure | Increased | Minimal direct effect |
| Liver fat | May directly reduce | Reduces via weight loss |
| Lean mass preservation | Potentially better | Standard |
| Safety concern | Hyperglycemia risk | Well-tolerated |
Evidence Quality
Pemvidutide Research
| Trial Phase | Status | Key Findings |
|---|---|---|
| Phase 1 | Completed | Safety established |
| Phase 2 (MOMENTUM) | Completed | ~15.6% weight loss (48 weeks) |
| Phase 2 (NASH) | Ongoing | Liver-focused endpoints |
| Phase 3 | Not started | Planned |
Current evidence:
- Phase 2 showed 15.6% weight loss at 48 weeks
- Improvements in liver enzymes observed
- Fat mass preferentially lost over lean mass (claimed)
- NASH-specific trials underway
Tirzepatide Research
| Trial Phase | Status | Key Findings |
|---|---|---|
| SURPASS | Completed | T2D efficacy established |
| SURMOUNT | Completed | Up to 22% weight loss |
| SYNERGY-NASH | Ongoing | NASH indication |
| Post-marketing | Active | Real-world data |
Established evidence:
- Robust Phase 3 data in T2D and obesity
- 20-22% weight loss in obesity trials
- NASH trials ongoing (not yet approved for this)
- Extensive safety database
Efficacy Comparison
Weight Loss
| Metric | Pemvidutide | Tirzepatide |
|---|---|---|
| Trial duration | 48 weeks | 72 weeks |
| Weight loss | ~15.6% | ~22% |
| Trial phase | Phase 2 | Phase 3 |
Important: These results are from different trial phases and populations; direct comparison has limitations.
Body Composition
| Measure | Pemvidutide | Tirzepatide |
|---|---|---|
| Fat mass loss | Emphasized | Primary outcome |
| Lean mass preservation | Claimed advantage | Standard for class |
| Body composition data | Limited | Some available |
Pemvidutide’s claim: Glucagon agonism may help preserve lean mass during weight loss by increasing energy expenditure rather than purely reducing intake. This requires validation in larger trials.
Evidence Strength Comparison
| Factor | Pemvidutide | Tirzepatide |
|---|---|---|
| Peer-reviewed studies | Limited | Extensive |
| Phase 3 trials | None | Multiple completed |
| Total patients studied | Hundreds | Thousands |
| Long-term safety | Unknown | Established |
| Overall quality | Low (Phase 2) | High |
NASH/MASH Potential
Pemvidutide for Liver Disease
| Factor | Status |
|---|---|
| Mechanism rationale | Glucagon promotes hepatic fat oxidation |
| Clinical data | Phase 2 ongoing |
| Liver enzyme effects | Improvements observed |
| Histologic outcomes | Pending |
Tirzepatide for Liver Disease
| Factor | Status |
|---|---|
| Mechanism | Indirect via weight loss |
| SYNERGY-NASH trial | Phase 3 ongoing |
| Early liver data | Encouraging |
| Approval status | Not yet approved for NASH |
Side Effects
Pemvidutide (Phase 2 Data)
| Side Effect | Incidence | Notes |
|---|---|---|
| Nausea | Common | GLP-1 class effect |
| Vomiting | Common | Expected |
| Diarrhea | Moderate | — |
| Hyperglycemia risk | Theoretical | Glucagon effect counterbalanced |
| Heart rate increase | Observed | Monitoring required |
Tirzepatide (Established)
| Side Effect | Incidence | Notes |
|---|---|---|
| Nausea | 12-33% | Dose-dependent |
| Diarrhea | 12-21% | Usually transient |
| Vomiting | 5-12% | Improves with titration |
| Constipation | 6-12% | Common |
Theoretical Concerns
Pemvidutide:
- Glucagon agonism could theoretically raise blood glucose
- Current data suggests GLP-1 component compensates
- Long-term cardiovascular effects unknown
- Heart rate increases warrant monitoring
Tirzepatide:
- Well-characterized GI tolerability
- Rare pancreatitis risk
- Thyroid C-cell warnings (precautionary)
Regulatory Status
| Aspect | Pemvidutide | Tirzepatide |
|---|---|---|
| FDA (T2D) | Not pursued | Approved (Mounjaro) |
| FDA (Obesity) | Not approved | Approved (Zepbound) |
| FDA (NASH) | Not approved | Not approved |
| Development stage | Phase 2 | Phase 3/Post-marketing |
| Availability | Clinical trials | Prescription |
Differentiation Strategy
Why Glucagon Agonism?
Altimmune’s rationale for including glucagon:
- Increases energy expenditure (thermogenesis)
- May preserve lean mass during weight loss
- Direct hepatic lipid oxidation for NASH
- Potentially different patient response profile
Tirzepatide’s GIP Advantage
Lilly’s rationale for GIP agonism:
- Enhances GLP-1 effects
- Well-tolerated combination
- Proven efficacy in large trials
- Favorable glucose control
Who Might Consider Each
Tirzepatide (Available Now):
- Type 2 diabetes patients
- Chronic weight management with BMI criteria
- Those wanting proven, approved therapy
- Standard first-line consideration
Pemvidutide (If Approved):
- Must await clinical trial completion
- May be positioned for NASH/MASH
- Patients interested in body composition benefits
- Those who haven’t responded to other agents
Summary
| Factor | Pemvidutide | Tirzepatide |
|---|---|---|
| Evidence quality | Low (Phase 2) | High (approved) |
| Weight loss | ~15.6% (48 wks) | ~22% (72 wks) |
| Mechanism | GLP-1/Glucagon | GLP-1/GIP |
| NASH potential | Central focus | Also in development |
| Availability | Clinical trials | Prescription |
| Lean mass preservation | Claimed advantage | Standard |
Key takeaway: These represent different dual agonist strategies. Tirzepatide is approved with robust data. Pemvidutide’s glucagon-based approach shows promise, particularly for NASH, but requires Phase 3 validation. The question of which dual combination is optimal remains under investigation.
This comparison is for educational purposes only. Pemvidutide is not FDA-approved. Tirzepatide requires a prescription. Consult a healthcare provider for treatment decisions.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.